Back to results
US 8,008,474 B2Granted
siRNA targeting KRAS
AssigneeDharmacon, Inc.
InventorsAnastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
Life of this patent
Estimating the term…
Abstract
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
Claims20
An siRNA molecule, wherein said siRNA molecule consists of:
- (a) a duplex region;
- and (b) either no overhang regions or at least one overhang region, wherein each overhang region contains six or fewer nucleotides, wherein the duplex region consists of a sense region and an antisense region, wherein said sense region and said antisense region together form said duplex region and said antisense region and said sense region each 19-30 nucleotides in length and said antisense region comprises a sequence that is the complement of ID NO:
- 452.
A chemically synthesized double stranded siRNA molecule, wherein:
- (a) each strand of said double stranded siRNA molecule is between 19 and 30 nucleotides in length;
- and
- (b) one strand of said siRNA molecule comprises a sequence that is the complement of SEQ ID NO:
- 452.
1 more element
Dependencies are inferred from the claim text.